75 mg/day (treatment nonresponder mean) 54% response rate on CGI (22% placebo) Total ADHD RS score decrease of 41% (vs 14% placebo) [55] 87 mg/day placebo (mean) 37% response rate on CGI and AISRS ...

The app will be used for 25 minutes daily, seven days a week, over six weeks, with its effects measured using the ADHD-RS-IV inattentive subscale. Shionogi has already demonstrated proof-of ...

Background The stimulant methylphenidate (MPH) has been a mainstay of treatment for attention-deficit/hyperactivity disorder (ADHD) for many years. Owing to the short ...

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...